Microbiome Connect: USA 2023
BOSTON, USA
14-16 November, 2023

Where the Microbiome Industry Comes Together

Join a like-minded community of 250 scientists and entrepreneurs as passionate about the microbiome as you are. Microbiome Connect was born with the simple mission to bring innovative products to patients, and we bring together experts approaching this challenge from every angle. Together, we provide a platform that allows you to unleash the full therapeutic power of the microbiome.



BOOK NOW                                                AGENDA HIGHLIGHTS

3
full days of content
65
speakers
250
industry leading experts
8000
1-2-1 bookable meeting opportunities

With a full slate of main-stage keynotes, breakout sessions, networking and more across three jam-packed days, you and your team will gain the connections and insights you need across three key pillars.

Regulation

Gain tangible regulatory solutions to decrease the amount of time needed for new therapeutics to reach the market.
With more FDA representatives presenting than any other microbiome therapeutics event, alongside leading regulatory consults, obtain the clarity you need to ensure your product meets its regulatory milestones.

Investment

If fundraising is your goal, Microbiome Connect is the place to be. We’ll have more investors in the room than ever before, all with one goal in mind: to evaluate microbiome investment prospects.
Hear how to make your innovation stand out from the crowd and meet the right investor for your investment goals, whether you’re looking for early or late-stage investment.

Product Development

Deep dive into the most need-to-know data, technologies and strategies in drug discovery, clinical development and manufacturing across multiple therapeutic areas.
Maximize your ROI with our user-friendly 1-2-1 partnering platform, ensuring you meet the right people for your research & business needs.

50+ TRAILBLAZING SPEAKERS

From every part of the microbiome industry, our expert speakers will take to the stage to share what’s happening now in the world of microbiome – and what’s going to happen next.

 

SEE ALL SPEAKERS

 

Chris McChalicher

Vice President, CMC Technical Development
Seres Therapeutics

Chris McChalicher

Vice President, CMC Technical Development
Seres Therapeutics

Chris McChalicher

Vice President, CMC Technical Development
Seres Therapeutics
 

Ken Blount

VP of Microbiome Research, Ferring Pharmaceuticals, and CSO, Rebiotix Inc., a Ferring Company

Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center.

Ken Blount

VP of Microbiome Research, Ferring Pharmaceuticals, and CSO, Rebiotix Inc., a Ferring Company

Ken Blount

VP of Microbiome Research, Ferring Pharmaceuticals, and CSO, Rebiotix Inc., a Ferring Company

Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.

 

Terri Young

Executive Vice President, Chief Commercial and Strategy Officer
Seres Therapeutics

Terri Young

Executive Vice President, Chief Commercial and Strategy Officer
Seres Therapeutics

Terri Young

Executive Vice President, Chief Commercial and Strategy Officer
Seres Therapeutics
 

Trent Munro

Senior Vice President of Therapeutics
Microba Life Sciences

Trent Munro

Senior Vice President of Therapeutics
Microba Life Sciences

Trent Munro

Senior Vice President of Therapeutics
Microba Life Sciences
 

Staffan Stromberg

Chief Executive Officer
Infant Bacterial Therapeutics

Staffan Stromberg

Chief Executive Officer
Infant Bacterial Therapeutics

Staffan Stromberg

Chief Executive Officer
Infant Bacterial Therapeutics
 

Hervé Affagard

Chief Executive Officer
MaaT Pharma

Hervé Affagard

Chief Executive Officer
MaaT Pharma

Hervé Affagard

Chief Executive Officer
MaaT Pharma
 

Daniel Cuoto

Chief Operating Officer
Vedanta Bio

Daniel Cuoto

Chief Operating Officer
Vedanta Bio

Daniel Cuoto

Chief Operating Officer
Vedanta Bio
 

Nikole Kimes

Chief Executive Officer
Siolta Therapeutics

Nikole Kimes

Chief Executive Officer
Siolta Therapeutics

Nikole Kimes

Chief Executive Officer
Siolta Therapeutics
 

Denise Kelly

Investment Advisor
Seventure Partners

Denise Kelly

Investment Advisor
Seventure Partners

Denise Kelly

Investment Advisor
Seventure Partners
 

Caroline Mitchell

Professor
Harvard University

Caroline Mitchell

Professor
Harvard University

Caroline Mitchell

Professor
Harvard University
 

Andrew Nealon

Partner and Chief Analyst
Joyance

Andrew Nealon

Partner and Chief Analyst
Joyance

Andrew Nealon

Partner and Chief Analyst
Joyance
 

Bharat Dixit

Chief Technology Officer
Adiso Therapeutics

Bharat Dixit

Chief Technology Officer
Adiso Therapeutics

Bharat Dixit

Chief Technology Officer
Adiso Therapeutics

Agenda Highlights


Workshop Streamlining the Regulatory Process to Decrease the Time to Market

Collaboration is vital to support innovation in the microbiome arena and ensure that products get to patients as swiftly as possible. This interactive workshop, featuring short presentations and roundtable discussions, allows you to connect with like-minded individuals to overcome some of the key bottlenecks in the regulation of microbiome-based drugs, including: clinical trial design, endpoint and biomarker selection, use of expedited review pathways and product nomenclature.

Panel Discussion: Money & The Microbiome

After a tumultuous couple of years, large pharma and investors alike are poised and ready to return to the heights of the biotech capital markets. How can microbiome biotechs make sure that their data captures the eye of investors? What gets pharma excited about working with a particular biotech, and are there specific traits that could convince pharma to dip their toes back into the world of microbial innovation?

Panellists

Author:

Elran Haber, PhD

Chief Executive Officer
Biomica

Elran Haber, PhD

Chief Executive Officer
Biomica

Author:

Andrew Nealon

Partner and Chief Analyst
Joyance

Andrew Nealon

Partner and Chief Analyst
Joyance

Author:

Caleb Bell

Venture Partner
CSB

Caleb Bell

Venture Partner
CSB

Author:

Denise Kelly

Investment Advisor
Seventure Partners

Denise Kelly

Investment Advisor
Seventure Partners

Can ‘In Silico’ Fermentation Optimize Bioprocessing

• Discussing the application of in-silico simulation (CarbonMirror Platform) to bioprocessing

• Understanding the limitations and benefits of in-silico simulation, choosing the optimum conditions for maximum yield and tackling biofilms

Author:

Nik Sharma

Chief Executive Officer
BioCortex

Nik Sharma

Chief Executive Officer
BioCortex

Agenda

"If being part of the Microbiome Therapeutics conversation is important to your research or business goals, this is the place to be." - List Labs

Our conference programme features the latest insights from the industry’s top companies and key thoughts-leaders, tackling the most pertinent issues and trends in the industry.

With three stages of content, you’ll be able to tailor your perfect agenda to meet your specific business needs – allowing you & your team to gain the tangible intel you need to fast-track your product development over the next 12 months.

download the agenda

Sponsorship Prospectus

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us